Belsomra vs Dayvigo for Women: A Head-to-Head Comparison Across Every Life Stage

What Are Belsomra and Dayvigo, and How Do They Work?

Both drugs block orexin receptors in the brain. Orexin (also called hypocretin) is the neuropeptide that keeps you awake. Rather than forcing sedation through GABA pathways the way older benzodiazepines do, these drugs simply turn off the wake signal. For women, that mechanism distinction matters: GABA-based sleep drugs suppress REM sleep and carry higher fall and fracture risk, particularly relevant after menopause when bone density already declines.

Suvorexant (Belsomra) was FDA-approved in August 2014 at doses of 5 mg to 20 mg. Lemborexant (Dayvigo) received FDA approval in December 2019 at 5 mg and 10 mg. The two drugs share a class but differ in receptor binding kinetics: lemborexant dissociates from orexin receptors faster in the morning, which is one reason its next-day impairment profile looks cleaner in head-to-head pharmacodynamic work.

Why Orexin Matters Differently for Women

Women are roughly twice as likely as men to develop insomnia across their lifetimes, with incidence spiking sharply in perimenopause. Orexin neurons in the hypothalamus have estrogen receptors. As estrogen falls during menopause transition, orexin signaling becomes dysregulated, which may amplify both nighttime waking and daytime sleepiness. Targeting orexin directly therefore has a biologically plausible advantage in women with hormone-driven sleep disruption, though head-to-head data in perimenopausal women specifically remain sparse.

Receptor Kinetics: A Practical Difference

Lemborexant's faster off-rate from OX1R and OX2R receptors translates to a shorter functional duration of action despite a half-life of approximately 17 to 19 hours. Suvorexant's half-life is approximately 12 hours, but its receptor occupancy lingers longer in some individuals, particularly those with slower CYP3A4 metabolism. Women generally have lower CYP3A4 activity than men (activity can drop further in late pregnancy), which means drug exposure can run higher at identical doses.

Efficacy: What the Trials Actually Show

The clearest way to compare these drugs is to look at the key trials side by side, then examine what the data says about women specifically.

Suvorexant: Herring et al. (Lancet Neurology 2019) and the Phase 3 Program

The Herring et al. Lancet Neurology 2014 trial randomized 1,021 adults to suvorexant 15/20 mg or 20/40 mg versus placebo over three months. Suvorexant significantly reduced subjective time to sleep onset and wake-after-sleep-onset (WASO) at every timepoint. Women made up roughly half the trial population, but sex-stratified efficacy data were not the primary focus. The drug met its co-primary endpoints of subjective WASO and time to sleep onset versus placebo. Dose-dependent next-morning somnolence was the most common adverse effect, occurring in approximately 7% of the 20 mg group.

Lemborexant: SUNRISE-1 and SUNRISE-2

The SUNRISE-1 trial was a 30-night randomized trial comparing lemborexant 5 mg, lemborexant 10 mg, and zolpidem extended-release 6.25 mg in adults 55 and older with insomnia disorder. The older-adult population skewed female (approximately 64% women). Lemborexant 5 mg and 10 mg both outperformed placebo on polysomnographic sleep onset latency (LPS) and WASO. Critically, lemborexant 5 mg produced significantly less next-morning postural instability than zolpidem-ER, a finding with real clinical weight for postmenopausal women at fracture risk. SUNRISE-2 extended efficacy evidence to 12 months at the same doses.

Driving Simulation: Where Lemborexant Pulls Ahead

A head-to-head pharmacodynamic study comparing lemborexant 10 mg, suvorexant 20 mg, and zolpidem-ER 6.25 mg found that lemborexant 10 mg and suvorexant 20 mg produced similar next-morning driving impairment, but lemborexant 5 mg caused no more impairment than placebo on a standardized road-tracking test. Suvorexant at any approved dose did not achieve that clean a profile in this comparison. For women who drive early in the morning, or who get up at night with children or for caregiving, this is a practical distinction.

Sleep Architecture

Neither drug suppresses REM sleep at standard doses, which differentiates both from benzodiazepines and Z-drugs (zolpidem, eszopiclone). Preserving REM sleep matters particularly for perimenopausal and postmenopausal women because REM disruption worsens mood, memory consolidation, and emotional regulation, all already under pressure during menopause transition.

How Each Drug Behaves Across Female Life Stages

Reproductive Years (Ages 18 to 45)

Chronic insomnia in reproductive-age women often links to PCOS, anxiety disorders, shift-work schedules, or postpartum disruption rather than to primary insomnia alone. Before prescribing either DORA in this group, clinicians should evaluate whether an underlying hormonal driver (progesterone deficiency in the luteal phase, PCOS-related cortisol excess) is amenable to more targeted treatment. Both suvorexant and lemborexant are Schedule IV controlled substances, and prescribing them long-term in reproductive-age women without contraception counseling is a gap in care.

Perimenopause (Typically Ages 45 to 55)

Perimenopausal insomnia is frequently driven by vasomotor symptoms: hot flashes fragment sleep at 2 a.m. And 4 a.m., then anxiety about sleep drives conditioned arousal. A DORA may reduce WASO without touching the hot flash itself. The Menopause Society (formerly NAMS) 2023 position statement notes that menopausal hormone therapy (MHT) is the most effective treatment for vasomotor-driven sleep disruption when initiated within 10 years of menopause onset. Adding a DORA on top of MHT may benefit women with residual sleep-onset difficulty after vasomotor symptoms are controlled, but that combination has not been studied in a dedicated trial.

Postmenopause (Ages 55 and Older)

This is the group with the most direct trial data. SUNRISE-1 enrolled predominantly postmenopausal women, and lemborexant 5 mg showed a statistically significant advantage over zolpidem-ER on postural stability the morning after dosing, a clinically meaningful finding given that fall-related hip fracture mortality in postmenopausal women is substantial. Suvorexant has also shown efficacy in older adults, including a dedicated trial in Alzheimer's-related insomnia, but it lacks the same postural stability data in direct comparison.

For postmenopausal women on bone-active agents (bisphosphonates, denosumab), reducing fall risk is as important as treating the sleep itself. Lemborexant 5 mg is the preferred starting point here.

PCOS-Related Sleep Disruption

Women with PCOS have higher rates of obstructive sleep apnea (OSA) than age-matched controls, driven partly by hyperandrogenism and obesity. Neither suvorexant nor lemborexant is appropriate as monotherapy when OSA is the primary driver of sleep disruption. Both drugs can, in theory, worsen respiratory depression during apneic episodes. OSA should be screened for and treated before starting any DORA in women with PCOS.

Pregnancy and Lactation Safety (Required Reading Before Prescribing)

Neither suvorexant nor lemborexant has established safety in human pregnancy. Both should be avoided.

Suvorexant in Pregnancy

The FDA label for suvorexant carries no formal letter category under the current system but includes animal reproduction studies showing fetal harm at exposures below the human therapeutic range. No adequate, well-controlled human pregnancy studies exist. Suvorexant crosses the blood-brain barrier readily and is expected to cross the placenta. Women of reproductive potential prescribed suvorexant should use reliable contraception.

Lemborexant in Pregnancy

Lemborexant's FDA label similarly contains animal reproduction data showing increased embryo-fetal mortality at doses yielding exposures approximately 16 times the human maximum recommended dose. No human pregnancy data are available. Because orexin signaling is active during fetal neurodevelopment, theoretical concerns about orexin pathway disruption exist, though these have not been studied in human neonates.

Lactation

Both drugs are detected in the milk of lactating animals. Human lactation data are absent for both agents. Given the sedation mechanism, transfer of either drug into breast milk could theoretically sedate a nursing infant. The standard clinical recommendation is to avoid both drugs during breastfeeding. If a nursing mother requires pharmacologic sleep support, short-term low-dose doxylamine (Unisom) or diphenhydryl alternatives are generally considered lower risk, though still not ideal. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line recommendation in postpartum women.

Contraception Guidance

Any woman of reproductive potential starting suvorexant or lemborexant should be counseled to use a reliable contraceptive method. If pregnancy is planned, both drugs should be discontinued with appropriate washout. There is no established minimum washout period in published guidance, but given suvorexant's half-life of approximately 12 hours and lemborexant's of approximately 17 to 19 hours, clinical clearance occurs within approximately five half-lives (roughly 2 to 4 days). Longer washout is prudent for women who have used either drug for extended periods.

Side-Effect Profiles: What Women Report

Daytime Somnolence

The most common complaint with both drugs is residual next-morning sedation. With suvorexant at 20 mg, approximately 7% of trial participants reported somnolence. Lemborexant 10 mg shows a comparable rate. At 5 mg, lemborexant's somnolence rate approaches placebo in SUNRISE-1.

Sleep Paralysis and Hypnagogic Hallucinations

Both drugs, by suppressing the wake drive, can produce REM-intrusion phenomena: sleep paralysis, vivid dreams, and hypnagogic or hypnopompic hallucinations. These are more common at higher doses. Women with a history of trauma or PTSD may find these experiences distressing. CBT-I and lower starting doses mitigate risk.

Falls and Balance

This matters most for postmenopausal women. The direct postural instability data from SUNRISE-1 favor lemborexant 5 mg. Suvorexant's effect on balance has been less systematically quantified in women over 65.

Mood Effects

Suvorexant carries an FDA boxed-warning-adjacent language noting that it can worsen depression and trigger suicidal ideation in susceptible individuals. The same signal exists for lemborexant, consistent with the class. For perimenopausal women who already experience mood lability, this warrants a direct conversation before initiating either drug.

Drug Interactions Relevant to Women

Both drugs are primarily metabolized by CYP3A4. Women are generally more sensitive to CYP3A4 inhibitors than men because baseline CYP3A4 activity is already modestly lower in females.

Drugs commonly used by women that affect CYP3A4 include:

• Oral contraceptives: Some formulations mildly inhibit CYP3A4, slightly increasing DORA exposure.
• Fluconazole (Diflucan): A strong CYP3A4 inhibitor frequently used for vaginal candidiasis. Co-administration can substantially increase suvorexant or lemborexant blood levels. Dose reduction is warranted.
• Clarithromycin or erythromycin: Prescribed for certain gynecologic infections; both are moderate-to-strong CYP3A4 inhibitors.
• St. John's Wort: A CYP3A4 inducer used by some perimenopausal women for mood support. This could reduce DORA efficacy.

The FDA label for suvorexant recommends a maximum dose of 10 mg when used with moderate CYP3A4 inhibitors and advises against use with strong CYP3A4 inhibitors entirely. Lemborexant carries the same class-level interaction guidance.

Should You Switch from Belsomra to Dayvigo?

Switching is reasonable to consider in specific clinical situations. It is not automatic, and the decision should be individualized.

Situations Where Switching May Help

• You are experiencing more next-morning grogginess on suvorexant 10 mg or 20 mg than you would like, particularly if you need to drive early.
• You are postmenopausal, have osteopenia or osteoporosis, and fall risk is a clinical concern.
• You are starting a medication that moderately inhibits CYP3A4 (fluconazole intermittently, for example) and need to reduce DORA exposure.
• Suvorexant at the lowest effective dose is simply not covered by your plan, and lemborexant is.

Situations Where Switching Is Unlikely to Add Benefit

• You are already doing well on suvorexant 10 mg with no residual sedation and no safety concerns. Changing a working regimen for its own sake carries risk of rebound insomnia during the transition.
• Your insomnia is primarily driven by uncontrolled vasomotor symptoms, anxiety, or OSA. Switching DORAs will not fix the underlying driver.
• Cost: both drugs remain brand-only as of early 2025, with similar out-of-pocket costs without insurance coverage.

How to Switch Practically

There is no published cross-taper protocol for suvorexant-to-lemborexant switching. Because both are DORAs acting on the same receptors, direct substitution the following night at the starting dose of the new drug (lemborexant 5 mg) is clinically reasonable. Some women experience 1 to 3 nights of lighter sleep during the transition as receptor occupancy normalizes. Avoid switching during a period of high sleep-disruption risk (new baby, travel, major life stressor).

Who This Medication Is Right For (and Who Should Not Use It)

Right for

• Postmenopausal women with chronic insomnia who have failed CBT-I or have moderate-to-severe insomnia disorder (ISI score above 14) and no untreated OSA.
• Perimenopausal women whose vasomotor symptoms are controlled by MHT but who have residual conditioned insomnia or sleep-maintenance difficulty.
• Women who cannot tolerate Z-drugs due to sleepwalking, amnesia episodes, or next-morning impairment.
• Older women at fall risk where lemborexant 5 mg is the preferred agent based on SUNRISE-1 postural stability data.

Not right for

• Pregnant women or those planning pregnancy in the near term. Both drugs carry animal teratogenicity signals and no human safety data.
• Breastfeeding women. Infant sedation risk from milk transfer cannot be ruled out.
• Women with untreated or severe OSA. Orexin antagonism does not protect the airway; apneic episodes could worsen.
• Women with narcolepsy. Blocking orexin in someone who already has orexin deficiency is contraindicated.
• Women with severe hepatic impairment. Both drugs accumulate with liver disease; suvorexant is not recommended, lemborexant requires dose adjustment.

Evidence Gaps Specific to Women

Women have been present in these trials, but sex-stratified analyses are limited. Several gaps deserve candor.

• Perimenopausal insomnia specifically: No randomized trial has tested either DORA in women specifically defined as perimenopausal with concurrent vasomotor symptoms, either alone or in combination with MHT. Benefit in this group is extrapolated from mixed-age insomnia trials.
• PCOS-related insomnia: No published trial addresses either drug in women with PCOS, despite the high insomnia prevalence in this population.
• Hormonal contraceptive interaction: The modest CYP3A4 inhibition from combined oral contraceptives has not been formally studied in the context of DORA dosing. The magnitude of any exposure increase is probably small but unquantified.
• Sex-specific pharmacokinetics: Women's lower average body weight and CYP3A4 activity suggest that the effective exposure from a 20 mg suvorexant dose may be higher in women than in men at equivalent milligram doses, but the key trials did not report sex-stratified PK data.

Acknowledging these gaps is not a reason to avoid these drugs when clinically indicated. It is a reason to start at the lowest effective dose in women and to monitor response carefully.

The WomanRx Clinical Summary: Choosing Between Them

For most women starting a DORA today, lemborexant 5 mg is a reasonable first choice based on its cleaner next-morning impairment profile at the starting dose and its direct postural stability data in older women from SUNRISE-1. Suvorexant remains a reasonable option, particularly for women who have been stable on it without side effects.

The choice between them should never be made in isolation from the broader hormonal and life-stage context. A 48-year-old with perimenopausal hot flashes keeping her awake is not the same clinical picture as a 67-year-old with primary insomnia disorder after menopause. The drug may be the same; the workup and conversation should not be.

Both drugs require contraception counseling in reproductive-age women. Neither is appropriate in pregnancy. CBT-I remains the first-line treatment for chronic insomnia in every life stage, and DORAs work best as an adjunct to, not a replacement for, behavioral sleep intervention.

If you are currently taking suvorexant 20 mg and experiencing morning grogginess, ask your clinician specifically about dropping to 10 mg first before switching classes or agents. The lowest dose that reliably gets you through the night is always the correct dose.